Acoustic Cluster Therapy (ACT®)consists of clusters of gas-filled microbubbles and oil microdroplets.
During the last decade ACT® has been evaluated preclinically in various cancer models and combined with different drugs. It was first observed that ACT was able to increase the fluorescence from a tumor when sonoenhancement was combined with fluorescent macromolecules (Wamel 2016, Figure 1). Here it was found that already one minute after sonoenhancement, fluorescence had increased in the tumor compared to a non-treated control, followed by a fluorescence uptake that remained for several hours. Subsequently, ACT has been tested therapeutically in preclinical models of prostate cancer (Wamel 2016), pancreatic cancer (Kotopoulis 2016, Ng 2022), colon cancer (Bush 2019) and breast cancer (Bush 2020). The combination of ACT and drug was significantly better than the drug alone in all these studies, with quite large numbers of complete remissions. Combining ACT with the drug nab-paclitaxel for treatment of prostate cancer resulted in complete tumor remission in all tested animals. This shows that ACT provides sonoenhancement across very different cancer types and with different types of drugs, which increases the likelihood of seeing effects also in clinical trials as the tumor models collectively represents a variety of cancer biology.
Side effects and toxicity have also been tested in various small animal models during the last decade. During treatment, no bleeding or macroscopic damage was observed, and pathological evaluation has not identified microscopic damages. ACT was extensively tested for systemic toxicities, including studies in rats and dogs where ultrasound to the heart and liver was used to activate the ACT bubbles, and no significant adverse effects have been detected.
Continue reading “Improving cancer therapy using sonoenhancement with acoustic cluster therapy” »